May & Baker Nigeria plc (NGX: MAYBAKER)
Nigeria
· Delayed Price · Currency is NGN | Market Cap | 13.20B |
| Revenue (ttm) | 27.22B |
| Net Income (ttm) | 2.26B |
| Shares Out | 1.73B |
| EPS (ttm) | 1.31 |
| PE Ratio | 5.84 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,600 |
| Open | n/a |
| Previous Close | 7.65 |
| Day's Range | n/a |
| 52-Week Range | 4.75 - 8.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 28, 2025 |
About May & Baker Nigeria
May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. It operates through Pharmaceuticals and Beverage segments. The company offers pharmaceuticals, including anti-diabetic, anti-hypersensitive, anti-infective, anti-malaria, analgesic, cough and cold, and anxiolytics; and nature care products. It also provides beverage drinks, including bottled water under the Lily Water name; and hand and surface sanitizers under the Smartans name. ... [Read more]
Financial Performance
In 2023, May & Baker Nigeria's revenue was 19.70 billion, an increase of 37.46% compared to the previous year's 14.33 billion. Earnings were 1.08 billion, a decrease of -27.34%.
Financial StatementsNews
May & Baker to commercialise bitterleaf capsule, unveil bio-vaccine factory
“May & Baker has gone through stages since its inception on September 4, 1944, as Nigeria’s first pharmaceutical company." The post May & Baker to commercialise bitterleaf capsule, unveil bio-vaccine ...